Clearant Announces Highlights of Investor Presentation; Company Provides Details on New Direct Sales Strategy.

LOS ANGELES -- Clearant, Inc. (OTCBB:CLRI) today announced highlights of an investor presentation the Company's chief executive officer, Alain Delongchamp, delivered at the Dutton Associates "Recognizing Opportunity" conference in San Francisco on May 31, 2006. In the presentation, the Company outlined its plans to transition from a pure licensing provider to the tissue and biological industry to a direct distributor of Clearant Sterile Implants to surgeons, clinics and hospitals via a direct sales force.

"Due to a relatively small number of surgeons performing a high percentage of bone implant procedures, we believe that our newly created sales force will be highly effective in rapidly penetrating the market," said Mr. Delongchamp. "While the sales cycle to tissue banks through distributors represented a lengthy process, we feel that our ability to market directly to these influential thought and opinion leaders will dramatically reduce the sales cycle. During the coming months, we expect to build our sales force by hiring proven executives from the healthcare industry and to drive revenue growth from the shorter sales cycle."

Currently, the top fifteen markets in the U.S. represent in excess of $200 million in bone implant sales. The top 30-50 surgeons in these markets perform approximately 80% of the procedures, allowing the Company to be highly effective in its marketing activities.

Interested parties can access an audio replay of the webcast and accompanying slide presentation via the Internet by visiting the "Investors" section on the Company's Web site at www.clearant.com. The presentation will be archived on the Web site and available for 30 days.

About Clearant, Inc.

Clearant, Inc. is a leader in pathogen inactivation for biological products. Clearant has developed the patent-protected CLEARANT PROCESS, which substantially reduces all types of pathogens in biological products while maintaining the functionality of the underlying protein. The Company plans to distribute directly to surgeons, hospitals and clinics CLEARANT PROCESS sterile implants starting mid 2006; in addition, Clearant continues to license the CLEARANT PROCESS and provides its patented sterilization services to tissue banks and other biological products manufacturers. As of the end of 1Q 2006, Clearant had 10 license and service agreements with tissue banks. To-date more than 8,000 patients have been successfully implanted with a CLEARANT PROCESS sterile implants supplied by one of the Company's licensed partners. Whereas various competing sterilization methods only kill specific types of pathogens (such as bacteria or lipid-enveloped viruses) for specific products, the CLEARANT PROCESS reduces all types of pathogens for products across many market segments including tissue implants, plasma proteins, recombinant products, medical devices and blood products. Also, the CLEARANT PROCESS can be applied at various stages of product processing and/or manufacturing, including in the final packaging. For more information, please visit www.clearant.com.

Forward-Looking Statements 

Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995, in particular statements regarding the ability of the Company's direct sales force to penetrate the market for sterile implants. These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control, which may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, results of additional clinical studies, efficacy of the technology, intense competition and substantial regulation in the biotechnology industry, and additional risks discussed in the company's filings with the SEC, available on the SEC web site http://www.sec.gov.